

Serveur Académique Lausannois **SERVAL** serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Association of CRT1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.

Authors: Quteineh L, Preisig M, Rivera M, Milaneschi Y, Castelao E, Gholam-Rezaee M, Vandenberghe F, Saigi-Morgui N, Delacrétaz A, Cardinaux JR, Willemsen G, Boomsma DI, Penninx BW, Ching-López A, Conus P, Eap CB

Journal: Journal of affective disorders

Year: 2016 Jul 1

Issue: 198

Pages: 43-9

DOI: 10.1016/j.jad.2016.03.031

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Association of *CRTC1* polymorphisms with obesity markers in subjects from the general population with lifetime depression.

Lina Quteineh, MD, PhD (1), Martin Preisig, MD, MPH (2), Margarita Rivera, PhD (3-5), Yuri Milaneschi, PhD (6), Enrique Castelao, MSc (2), Mehdi Gholam-Rezaee, PhD (2), Frederik Vandenberghe, PharmD, MSc (1), Nuria Saigi-Morgui, PharmD, MSc (1), Aurélie Delacrétaz, MSc (1), Jean-René Cardinaux, PhD (7, 8), Gonneke Willemsen, PhD (9), Dorret I Boomsma, PhD (9), Brenda WJH Penninx, PhD (6), Ana Ching-López (4), Philippe Conus, MD (10), Chin B Eap, PhD (1,11)

¹ Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland.

² Centre of Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland.

³ Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.

⁴ CIBERSAM-University of Granada and Institute of Neurosciences Federico Olóriz, Centro de Investigación Biomédica, University of Granada, Spain.

⁵ MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

⁶ Department of Psychiatry, EMGO Institute for Health and Care Research and Neuroscience Campus Amsterdam, VU University Medical Center/GGZ inGeest, Amsterdam, The Netherlands.

⁷ Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland.

⁸ Child and Adolescent Psychiatric Clinic, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland.

⁹ Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands.

¹⁰ Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, Prilly Switzerland.

¹¹ School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.

For correspondence:

Prof CB. Eap

Hôpital de Cery,

1008 Prilly – Lausanne, Switzerland

Tel: 0041 21 314 26 04

Fax: 0041 21 314 24 44

Email: chin.eap@chuv.ch

Keywords: Obesity, major depressive disorder, psychiatric disorders, psychotropic drugs, pharmacogenetics, genetic polymorphisms.

Introduction:

Based on a growing body of evidence, it has been hypothesized that psychiatric disorders, such as schizophrenia and mood disorders, are causally related to or share common etiological pathways with obesity, suggesting that comorbid obesity and psychiatric disorders have related neurobiological bases (Farmer et al., 2008; Forty et al., 2014). Increased appetite, weight gain and obesity are common symptoms of depression (Blaine, 2008; Luppino et al., 2010). On the other hand, obese individuals were also found to have higher prevalence of depression (Luppino et al., 2010). Shared genetic factors were previously suggested (Afari et al., 2010; Comings et al., 1996; Rivera et al., 2012; Samaan et al., 2013), however, due to the pathological complexity of both conditions and the polygenic factors affecting them, many genetic factors are still to unravel. Additionally, due to heterogeneity of depression, genetic association studies could give conflicting results. One example is the fat mass and obesity-associated gene (*FTO*) for which the common *rs9939609-A* variant previously associated with increased body mass index (BMI) and obesity in several studies (Frayling et al., 2007; Qi et al., 2008; Scuteri et al., 2007) was shown to be negatively associated with depression in a meta-analysis of four large studies (Samaan et al., 2013). On the other hand, the same variant was found to be positively associated with depression in a recent large case-control study (Milaneschi et al., 2014), but this association was entirely driven by the atypical depression subtype (subtype characterized typically by increased appetite, weight gain and hypersomnia).

We previously showed an association between a coding single nucleotide polymorphism (SNP) within the *CREB-regulated transcription coactivator 1 (CRTC1)* gene (*rs3746266A>G*) and BMI in 3 independent psychiatric samples (brief description of these samples are mentioned in the Supplementary data and are found in ref (Choong et al.,

2013)). Carriers of the *rs3746266-G* variant showed significantly protective effect against obesity compared to non-carriers. The sex-stratified analysis in the 3 combined psychiatric samples showed a protective effect for the *G* allele both in men and women. However, the strongest and most clinically relevant association was observed in women younger than 45 years old. Although the effect was weaker, we also found a protective effect of the *T* allele of the *CRTC1 rs6510997C>T* (a proxy of *rs3746266A>G*, $r^2=0.7$) on fat accumulation in a large population-based sample (CoLaus), with the strongest association again in premenopausal women(Choong et al., 2013).

In animal models, we previously showed that mice lacking *CRTC1* exhibit neurobehavioral endophenotypes related to mood disorders, depression-related behavior and a blunted behavioral response to antidepressants(Breuillaud et al., 2012). *Crtc1* knockout mice also developed obese features, including obesity-related metabolic complications, under normal diets(Altarejos et al., 2008; Breuillaud et al., 2009). Altogether, these findings suggest that the *Crtc1* gene might play a common role in obesity and depression-related behavior.

In the present study, we aimed to examine whether *CRTC1* SNPs are associated with major depressive disorder (MDD), and to test the association of *CRTC1* SNPs with obesity markers in several large case-control samples with MDD. The same *CRTC1* SNPs (*rs3746266A>G* and *rs6510997C>T*) investigated previously(Choong et al., 2013) were used in the current study.

Patients and methods:

The associations between *CRTC1* polymorphisms and obesity markers were first tested in the PsyCoLaus sample and tested for replication in the Radiant and NESDA/NTR study. S1 present the main difference between these samples.

Discovery cohort: CoLaus|PsyCoLaus

Participants aged 35 to 75 years in this population-based cohort study (CoLaus; n=6,734) were recruited between June 2003 and May 2006 in Lausanne, Switzerland as previously described (Firmann et al., 2008). The assessments at baseline and at the first follow-up included cardiovascular risk factors such as BMI, fat mass, blood pressure, glucose and lipid profiles. In addition, a genome-wide association study was performed in all Caucasians (91% of the sample). All participants of CoLaus were asked to also participate in the psychiatric evaluations (PsyCoLaus (Preisig et al., 2009)), which included the semi-structured Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al., 1994; Preisig et al., 1999). The assignment of the lifetime diagnosis of MDD and the subtyping into atypical and non-atypical MDD was performed according to DSM-IV criteria. Complete physical and psychiatric data were available for 3,354 participants aged 35 to 65 year-old who completed the psychiatric evaluation either at the baseline or the first follow-up ($n_{\text{total}}=3362$). 1434 cases of lifetime depression were compared with 1,920 controls with no previous history of depression. Genotyping for the CoLaus/PsyCoLaus subjects was performed using the Affymetrix GeneChipR Human Mapping 500K array set. The *CRTC1* *rs6510997C>T* SNP was directly genotyped (Choong et al., 2013). The *CRTC1* *rs7257846T>C*, which is in linkage disequilibrium (LD) with *rs3746266A>G* ($r^2=0.93$), was imputed and analyzed (r^2_{hat} value was 0.70).

The Institutional Ethics Committee of the University of Lausanne approved the CoLaus and subsequently the PsyCoLaus study. All participants signed a written informed consent to participate in the study.

- **The Radiant study**

The Radiant study was founded from three studies: the Depression Case–Control (DeCC) study, Depression Network (DeNT) study and the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. The DeCC study is a multicentre case-control study conducted over three investigative sites in UK (London, Cardiff and Birmingham)(Cohen-Woods et al., 2009). The DeNT study is a family-based study that recruited sibling pairs affected with unipolar depression from eight European clinical sites and one in the USA(Farmer et al., 2004; McGuffin et al., 2005). Participants in the DeCC and DeNT studies were included if they had lifetime diagnosis of two or more episodes of MDD of at least moderate severity. Subjects in the GENDEP study were recruited from nine European centers if they experienced at least one depressive episode of at least moderate severity(Uher et al., 2009). Diagnosis of MDD was defined as of illness fulfilling ICD–10 and/or DSM–IV criteria and was ascertained using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview in all three studies(Wing et al., 1990). Control subjects were recruited via the Medical Research Council general practice research framework(Sham et al., 2000). They were screened for lifetime absence of any psychiatric disorder using a modified version of the Past History Schedule(McGuffin et al., 1986). Height and weight were self-reported. All cases and controls were of white European ancestry. Genotyping for the Radiant subjects was performed using the Illumina HumanHap610-Quad BeadChips by the Centre National de Génomique (CNG), Evry, France, as previously described(Lewis et al., 2010). *CRTC1* rs3746266A>G was successfully imputed using *the Beagle Program* (BEAGLE Version 3.0

Copyright (c) 2007–2010 Brian L Browning), with imputation quality >0.8 . The *CRTC1 rs2075017T>C*, which is in complete linkage disequilibrium (LD) with *the rs6510997C>T*, was also selected for the association analyses.

Approval was obtained from the local research ethics committees/institutional research boards of all of the participating sites. All participants provided written informed consent.

- **NESDA/NTR study:**

This sample consisted of 4,663 unrelated participants of European ancestry from the Netherlands Study of Depression and Anxiety (NESDA)(Penninx et al., 2008) (1,636 cases and 425 controls) and from the Netherlands Twin Registry (NTR)(Boomsma et al., 2006) (132 cases and 2,470 controls). The diagnosis of lifetime and/or current MDD according to DSM-IV was ascertained using the Composite Interview Diagnostic Instrument. Weight and height were measured at the study clinic during the visit for NESDA(Penninx et al., 2008), and during the home visit for NTR-Biobank(Willemsen et al., 2010). Genotyping was performed on multiple chip platforms in (partially overlapping) different subsets of the total sample (Affymetrix-Perlegen 5.0, Illumina 370K, Illumina 660K, Illumina Omni 1M and Affymetrix 6.0) and data were imputed using the 1000 Genomes phase 1 INTEGRATED RELEASE version 3 ALL panel (r^2 hat value was 0.99 for *rs6510997C>T* and 0.77 for *rs3746266A>G*).

The NESDA/NTR study was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Center, Amsterdam, and all subjects provided written informed consent.

Statistical analysis:

For association studies, chi-square (Chi^2) or Fisher exact tests for binomial variables were used. Differences in genotype frequencies as well as deviation from Hardy-Weinberg equilibrium were assessed using Chi^2 test. All genetic analyses for *CRTC1* SNPs were performed using a dominant model (wild type vs. variant allele carriers), the same model used for the previously mentioned psychiatric samples (Choong et al., 2013).

Multivariable regression analyses were used to test the association between the *CRTC1* SNPs and MDD adjusting for age, sex and BMI. For PsyCoLaus data, a Generalized Linear Model (GLM) adjusted for age and sex was used to test the association between *CRTC1* *rs6510997C>T* polymorphism and obesity markers (BMI, fat mass and waist circumference) using SAS 9.3 version (SAS Institute Inc., Cary, NC, USA). In a first step, we tested for the interaction between *CRTC1* SNPs and MDD status for an effect on obesity markers. For the Radiant and NESDA/NTR studies BMI was the only available obesity marker. For the data of these studies, linear regression models adjusted for age, sex and principal components were used to test the association between *CRTC1* polymorphisms and BMI.

Results:**Demographic characteristics of the study samples:**

General characteristics of the PsyCoLaus sample are presented in S2. The Radiant study included 3148 subjects (2,338 cases and 810 controls), mean age \pm standard deviation (s.d.) was 43.9 \pm 12.8 years. Females represent nearly 68% of the study sample. Mean BMI in the total study sample was 25.9 kg/m² (s.d. 5.4). The NESDA/NTR study included 4,663 subjects, mean age \pm s.d. was 42.7 \pm 14.0 years. Females represent nearly 64% of the study sample. Mean BMI in the total study sample was 25.0 kg/m² (s.d. 4.5).

***CRTC1* polymorphisms and MDD:**

Genotype distribution in the overall study samples and among MDD cases and controls are presented in Table 1. Genotype distribution did not differ between MDD cases and controls in any of the three studies (Table 1). Multivariate analyses adjusted for age and sex confirmed the absence of an association between *CRTC1* polymorphisms and MDD in the three studies (data not shown).

***CRTC1* polymorphisms and obesity markers:**

PsyCoLaus

CRTC1 rs6510997C>T was significantly associated with fat mass in the global PsyCoLaus sample (Table 2). We observed interactions between *CRTC1 rs6510997C>T* and sex ($p=0.03$) as well as between this SNP and MDD status ($p=0.01$) regarding the fat mass, indicating a significantly stronger effect of this genetic variant in females and in subjects with MDD. Indeed, this SNP was significantly associated with lower fat mass in females but not in males. Similarly, this SNP was significantly associated with lower fat mass in subjects with MDD but not in controls (Table 2). Additionally, the 3-way interaction between *CRTC1 rs6510997C>T*, sex and MDD regarding the fat mass was not significant ($p=0.54$). In females, we did not find an interaction between the *CRTC1 rs6510997C>T* SNP and menopausal status and among depressed subjects there was no interaction between this SNP and the atypical depression subtype to affect the fat mass. Regarding the BMI and waist circumference there was no evidence of an interaction between *CRTC1 rs6510997C>T* and sex or MDD status and the SNP was not associated with these obesity markers (Table 2).

No difference on the associations between *CRTC1 rs6510997C>T* and fat mass was noticed by adjusting the GLM model to other available co-variables that could affect the gene association with obesity markers, like socioeconomic status, drug dependence, alcohol consumption, former and current tobacco consumer (S3). Nearly the same associations with obesity markers in PsyCoLaus were observed for *CRTC1 rs7257846T>C* (in strong LD with *rs3746266A>G*, $r^2=0.93$)(S4).

The Radiant and NESDA/NTR studies:

The *CRTC1 rs3746266A>G* SNP was associated with BMI in the total Radiant sample and exclusively in females (Table 3). By stratifying MDD cases and controls, the protective effect of the *rs3746266G-allele* was only observed in MDD cases, while no association was observed in controls. A weak association was observed between *CRTC1 rs2075017T>C* (in complete LD with the *rs6510997C>T*) and BMI in the Radiant sample (Table 3). Regarding the NESDA/NTR study, *CRTC1* SNPs were not associated with BMI (Table 4).

Discussion:

We previously showed a protective effect of the variant *CRTC1 rs3746266G-allele* on increased BMI in three independent psychiatric samples(Choong et al., 2013). The same protective effect was also observed in a population-based sample (CoLaus) between the *rs6510997T-allele* (in a strong LD with the *rs3746266G-allele*) and fat mass. However, the effect of the SNP was weaker compared to the psychiatric samples(Choong et al., 2013). In the present study, we were able to show in the psychiatrically evaluated sub-sample of CoLaus (PsyCoLaus) that the effect of *CRTC1 rs6510997C>T* on fat mass was restricted to subjects with a lifetime history of MDD. In these subjects, the *CRTC1 rs6510997T-allele*

showed a significant protective effect for the fat mass. Although there was no significant interaction between the *CRTC1* SNPs and MDD, similar trend regarding the BMI was observed in the Radiant sample (no fat mass data available in this sample), which included more severe treated cases with lifetime recurrent depression. The *CRTC1 rs3746266A>G* SNP only reached the level of statistical significance in MDD cases. However, these results could not be replicated in a third case-control sample with lifetime depression, the NESDA/NTR study.

CRTC1 rs6510997C>T was associated with fat mass exclusively among depressive cases but not unaffected individuals in the PsyCoLaus sample. This association in depressed subjects did not differ in function of the depression subtypes (atypical versus others). Such an association with the BMI was not observed in the whole PsyCoLaus sample, but *CRTC1* SNPs were associated with BMI in the Radiant study. BMI may less accurately capture adiposity than estimated fat mass using bioimpedance (Marques-Vidal et al., 2009; Prentice and Jebb, 2001). Using the whole CoLaus sample, previous work established that fat mass enables capture of 3 times more subjects with high cardiovascular risk than BMI (Marques-Vidal et al., 2009) and we also showed that this sample is better powered to detect an association of the *rs6510997C>T* SNP with fat mass than with BMI (Choong et al., 2013). In the psychiatric samples, based on subjects at high risk of metabolic abnormalities because of the disorder and of the psychotropic medications, an association between *CRTC1* SNPs and BMI could be observed (Choong et al., 2013). Accordingly, the association between *CRTC1* SNPs and BMI observed in the Radiant study could be explained by the higher degree of severity of the disorder in this sample compared to that in the PsyCoLaus. Interestingly, post hoc analysis also revealed a significant protective effect of the *CRTC1 rs6510997C>T* SNP on BMI and

waist circumference in PsyCoLaus subjects with MDD (but not in the overall sample) which would be in line with our hypothesis that the impact of *CRTC1* variants on adiposity markers is restricted to affected subjects.

CRTC1 SNPs were associated with obesity markers in both PsyCoLaus and Radiant studies, but the association was entirely attributable to MDD cases. On the other hand, *CRTC1* SNPs were not associated with BMI in the NESDA/NTR study, neither in the whole sample, nor in the stratified MDD case-control analyses. Previously, PsyCoLaus and DeCC (from the Radiant study) samples detected a protective effect of the *FTO rs9939609-A* variant on MDD (Samaan et al., 2013), while in the NESDA/NTR study the SNP was positively associated with MDD, especially in the atypical depression subtype (Milaneschi et al., 2014). Therefore, an inconsistency was already observed before for these studies which could be partly explained by the heterogeneity of depression in genetic association studies.

Obesity results from an imbalance between energy intake and energy expenditure. Recent studies have shown that mice lacking the *Crtc1* gene eat more and have less energy expenditure than wild-type mice, thus developing an obese feature, including obesity-related metabolic complications, under normal diets (Altarejos et al., 2008; Breuillaud et al., 2009). These results suggest that *CRTC1* is playing a major role in the hypothalamic control of food intake. *CRTC1* is mainly expressed in the brain (Altarejos et al., 2008; Breuillaud et al., 2009; Conkright et al., 2003; Kovacs et al., 2007; Wu et al., 2006) where it may modulate leptin anorexic effect in the hypothalamus. In the cell, the inactive phosphorylated form of *CRTC1* is sequestered in the cytoplasm, and its migration to the nucleus requires the concomitant activation of the phosphatase calcineurin and the inactivation of kinases of the

5' adenosine monophosphate-activated protein kinase (AMPK) family (Altarejos and Montminy, 2011). Interestingly, psychotropic drugs may increase weight by selective and potent stimulation of hypothalamic AMPK (Minokoshi et al., 2004) which has been shown to regulate food intake and reverse the actions of the anorexigenic hormone leptin (Kim et al., 2007)

In the PsyCoLaus sample, an interaction between *CRTC1* SNP and sex was observed regarding the fat mass and the protective effect of the SNP was mainly observed in females from the global sample. The same protective effect of *CRTC1* SNP on BMI was also observed in females from the global Radiant sample. This is in line with our previous results in the psychiatric and CoLaus samples (Choong et al., 2013). This stronger association found in females compared to males could be caused by a differential role of the leptin mediating satiety pathway in the enhancement of *CRTC1* activity. Women have much higher leptin levels than men (Rosenbaum et al., 1996) and female sex was found to predict stronger weight gain during psychotropic treatment (Gebhardt et al., 2009). A hypothetical mechanism of the effect of *CRTC1* and its interaction with sex hormones was published previously (Choong et al., 2013). Additionally, a meta-analysis of GWAS reported an association of an intronic SNP of *CRTC1* (*rs10423674A>C*) with the age of menarche (Elks et al., 2010), supporting a potential interaction between sex hormones and *CRTC1*.

The *CRTC1* SNPs were not associated with depression in our three MDD case-control studies. Animal models lacking the *Crtc1* gene showed behavioral abnormalities and depression-related behavior (Breuillaud et al., 2012), but this finding could not be translated in our study. However, the functional activities of these SNPs in humans are still unknown and

possibly the complete absence of the *CRTC1* gene could lead to the observed behavioral disturbances in animal models, which is probably not the case for effect of the tested SNPs on *CRTC1* expression. On the other hand, the observed effect of the *CRTC1* SNPs on obesity markers was uniquely detected in subjects with MDD. The lack of association between *CRTC1* SNPs and obesity markers in controls from the PsyCoLaus and the Radiant samples explains the weak association previously found in the population-based sample(Choong et al., 2013). It also confirms our hypothesis in which psychiatric illness and/or treatment with potentially weight gain-inducing psychotropic drugs could play a role in genetically mediated energy homeostasis and that the effect of *CRTC1* variations on obesity markers was unmasked in this group of subjects. Interestingly, a study in animal models(Mastronardi et al., 2011) showed that rats exposed to a high-fat diet after stress and treatment for a short period with antidepressants, to have more body weight and size from 17 to 22 weeks following antidepressant discontinuation compared to rats with the same conditions but treated with saline(Mastronardi et al., 2011). These findings support our concept of persistent, long-term effects of pharmacological–environment interactions on body weight regulation, even if the exposure to these medications was in any period in their lifetime.

(Choong et al., 2013)

This study has several limitations. Estimated fat mass using bioimpedance was only measured in the PsyCoLaus sample while only BMI was the only adiposity marker measured in the replication samples. Additionally, height and weight were self-reported in the Radiant study, which might influence the accuracy of BMI measurements in this sample. Psychotropic medications were not available in the Radiant sample, therefore, associations between *CRTC1* SNPs and BMI in treated vs. untreated cases could not be calculated. Both *CRTC1* SNPs (*rs6510997C>T* and *rs3746266A>G*) were not always available in our three case-

control samples; however, SNPs with nearly complete LD ($r^2 > 0.9$) were selected and used as proxies, and results from these proxies could be generalized to our 2 *CRTC1* SNPs (meaning that the genotype present at one locus of the SNPs in LD is independent of the genotype at the second locus, both SNPs having the same allele frequency and could represent each other). On the other hand, SNPs were not always directly genotyped and different imputation methods with different imputation qualities were used which can potentially influence the results on the associations between different imputed *CRTC1* SNPs and obesity markers in our studies.

In conclusion, we showed in this study that *CRTC1* polymorphisms play no role in obesity markers in the general population and that the weak effect previously reported was totally driven by cases diagnosed with lifetime MDD. *CRTC1* seems to play an important role in the high prevalence of overweight and obesity specifically in psychiatric samples, a population at risk of developing obesity because of the disease itself and/or the medications. Whether *CRTC1* is implicated directly in the development of psychiatric diseases is still to be investigated.

References:

- Afari, N., Noonan, C., Goldberg, J., Roy-Byrne, P., Schur, E., Golnari, G., Buchwald, D., 2010. Depression and obesity: do shared genes explain the relationship? *Depress Anxiety* 27, 799-806.
- Altarejos, J.Y., Goebel, N., Conkright, M.D., Inoue, H., Xie, J., Arias, C.M., Sawchenko, P.E., Montminy, M., 2008. The Creb1 coactivator Crtc1 is required for energy balance and fertility. *Nat Med* 14, 1112-1117.
- Altarejos, J.Y., Montminy, M., 2011. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 12, 141-151.
- Blaine, B., 2008. Does depression cause obesity?: A meta-analysis of longitudinal studies of depression and weight control. *J Health Psychol* 13, 1190-1197.
- Boomsma, D.I., de Geus, E.J., Vink, J.M., Stubbe, J.H., Distel, M.A., Hottenga, J.J., Posthuma, D., van Beijsterveldt, T.C., Hudziak, J.J., Bartels, M., Willemsen, G., 2006. Netherlands Twin Register: from twins to twin families. *Twin Res Hum Genet* 9, 849-857.
- Breuillaud, L., Halfon, O., Magistretti, P.J., Pralong, F.P., Cardinaux, J.R., 2009. Mouse fertility is not dependent on the CREB coactivator Crtc1. *Nat Med* 15, 989-990.
- Breuillaud, L., Rossetti, C., Meylan, E.M., Merinat, C., Halfon, O., Magistretti, P.J., Cardinaux, J.R., 2012. Deletion of CREB-regulated transcription coactivator 1 induces pathological aggression, depression-related behaviors, and neuroplasticity genes dysregulation in mice. *Biol Psychiatry* 72, 528-536.
- Choong, E., Quteineh, L., Cardinaux, J.R., Gholam-Rezaee, M., Vandenberghe, F., Dobrin, M., Bondolfi, G., Etter, M., Holzer, L., Magistretti, P., Von Gunten, A., Preisig, M., Vollenweider, P., Beckmann, J.S., Pralong, F.P., Waeber, G., Kutalik, Z., Conus, P., Bochud, M., Eap, C.B., ODEX team, 2013. Influence of CRT1 polymorphisms on body mass index and fat mass in psychiatric patients and in the general adult population. *JAMA Psychiatry* 70, 1011-1019.
- Cohen-Woods, S., Gaysina, D., Craddock, N., Farmer, A., Gray, J., Gunasinghe, C., Hoda, F., Jones, L., Knight, J., Korszun, A., Owen, M.J., Sterne, A., Craig, I.W., McGuffin, P., 2009. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. *Hum Mol Genet* 18, 1504-1509.
- Comings, D.E., Gade, R., MacMurray, J.P., Muhleman, D., Peters, W.R., 1996. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. *Mol Psychiatry* 1, 325-335.
- Conkright, M.D., Canettieri, G., Srean, R., Guzman, E., Miraglia, L., Hogenesch, J.B., Montminy, M., 2003. TORCs: transducers of regulated CREB activity. *Mol Cell* 12, 413-423.
- Elks, C.E., Perry, J.R., Sulem, P., Chasman, D.I., Franceschini, N., He, C., Lunetta, K.L., Visser, J.A., Byrne, E.M., Cousminer, D.L., Gudbjartsson, D.F., Esko, T., Feenstra, B., Hottenga, J.J., Koller, D.L., Kutalik, Z., Lin, P., Mangino, M., Marongiu, M., McArdle, P.F., Smith, A.V., Stolk, L., van Wingerden, S.H., Zhao, J.H., Albrecht, E., Corre, T., Ingelsson, E., Hayward, C., Magnusson, P.K., Smith, E.N., Ulivi, S., Warrington, N.M., Zgaga, L., Alavere, H., Amin, N., Aspelund, T., Bandinelli, S., Barroso, I., Berenson, G.S., Bergmann, S., Blackburn, H., Boerwinkle, E., Buring, J.E., Busonero, F., Campbell, H., Chanock, S.J., Chen, W., Cornelis, M.C., Couper, D., Coviello, A.D., d'Adamo, P., De Faire, U., De Geus, E.J., Deloukas, P., Doring, A., Smith, G.D., Easton, D.F., Eiriksdottir, G., Emilsson, V., Eriksson, J., Ferrucci, L., Folsom, A.R., Foroud, T., Garcia, M., Gasparini, P., Geller, F., Gieger, C., Gudnason, V., Hall, P., Hankinson, S.E., Ferrel, L., Heath, A.C., Hernandez, D.G., Hofman, A., Hu, F.B., Illig, T., Jarvelin, M.R., Johnson, A.D., Karasik, D., Khaw, K.T., Kiel, D.P., Kilpelainen, T.O., Kolcic, I., Kraft, P., Launer, L.J., Laven, J.S., Li, S., Liu, J., Levy, D., Martin, N.G., McArdle, W.L., Melbye, M., Mooser, V., Murray, J.C., Murray, S.S., Nalls, M.A., Navarro, P., Nelis, M., Ness, A.R., Northstone, K., Oostra, B.A., Peacock, M., Palmer, L.J., Palotie, A., Pare, G., Parker, A.N., Pedersen, N.L., Peltonen, L., Pennell, C.E., Pharoah, P., Polasek, O., Plump, A.S., Pouta, A., Porcu, E., Rafnar, T., Rice, J.P., Ring, S.M., Rivadeneira, F., Rudan, I., Sala, C., Salomaa, V., Sanna, S., Schlessinger, D., Schork, N.J., Scuteri, A., Segre, A.V., Shuldiner, A.R., Soranzo, N., Sovio, U., Srinivasan, S.R., Strachan, D.P., Tammesoo, M.L.,

Tikkanen, E., Toniolo, D., Tsui, K., Tryggvadottir, L., Tyrer, J., Uda, M., van Dam, R.M., van Meurs, J.B., Vollenweider, P., Waeber, G., Wareham, N.J., Waterworth, D.M., Weedon, M.N., Wichmann, H.E., Willemsen, G., Wilson, J.F., Wright, A.F., Young, L., Zhai, G., Zhuang, W.V., Bierut, L.J., Boomsma, D.I., Boyd, H.A., Crisponi, L., Demerath, E.W., van Duijn, C.M., Econs, M.J., Harris, T.B., Hunter, D.J., Loos, R.J., Metspalu, A., Montgomery, G.W., Ridker, P.M., Spector, T.D., Streeten, E.A., Stefansson, K., Thorsteinsdottir, U., Uitterlinden, A.G., Widen, E., Murabito, J.M., Ong, K.K., Murray, A., 2010. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nat Genet* 42, 1077-1085.

Farmer, A., Breen, G., Brewster, S., Craddock, N., Gill, M., Korszun, A., Maier, W., Middleton, L., Mors, O., Owen, M., Perry, J., Preisig, M., Rietschel, M., Reich, T., Jones, L., Jones, I., McGuffin, P., 2004. The Depression Network (DeNT) Study: methodology and sociodemographic characteristics of the first 470 affected sibling pairs from a large multi-site linkage genetic study. *BMC Psychiatry* 4, 42.

Farmer, A., Korszun, A., Owen, M.J., Craddock, N., Jones, L., Jones, I., Gray, J., Williamson, R.J., McGuffin, P., 2008. Medical disorders in people with recurrent depression. *Br J Psychiatry* 192, 351-355.

Firmann, M., Mayor, V., Vidal, P.M., Bochud, M., Pecoud, A., Hayoz, D., Paccaud, F., Preisig, M., Song, K.S., Yuan, X., Danoff, T.M., Stirnadel, H.A., Waterworth, D., Mooser, V., Waeber, G., Vollenweider, P., 2008. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord* 8, 6.

Forty, L., Ulanova, A., Jones, L., Jones, I., Gordon-Smith, K., Fraser, C., Farmer, A., McGuffin, P., Lewis, C.M., Hosang, G.M., Rivera, M., Craddock, N., 2014. Comorbid medical illness in bipolar disorder. *Br J Psychiatry* 205, 465-472.

Frayling, T.M., Timpson, N.J., Weedon, M.N., Zeggini, E., Freathy, R.M., Lindgren, C.M., Perry, J.R., Elliott, K.S., Lango, H., Rayner, N.W., Shields, B., Harries, L.W., Barrett, J.C., Ellard, S., Groves, C.J., Knight, B., Patch, A.M., Ness, A.R., Ebrahim, S., Lawlor, D.A., Ring, S.M., Ben-Shlomo, Y., Jarvelin, M.R., Sovio, U., Bennett, A.J., Melzer, D., Ferrucci, L., Loos, R.J., Barroso, I., Wareham, N.J., Karpe, F., Owen, K.R., Cardon, L.R., Walker, M., Hitman, G.A., Palmer, C.N., Doney, A.S., Morris, A.D., Smith, G.D., Hattersley, A.T., McCarthy, M.I., 2007. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 316, 889-894.

Gebhardt, S., Haberhausen, M., Heinzl-Gutenbrunner, M., Gebhardt, N., Remschmidt, H., Krieg, J.C., Hebebrand, J., Theisen, F.M., 2009. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. *J Psychiatr Res* 43, 620-626.

Kim, S.F., Huang, A.S., Snowman, A.M., Teuscher, C., Snyder, S.H., 2007. Antipsychotic drug-induced weight gain mediated by histamine H₁ receptor-linked activation of hypothalamic AMP-kinase. *PNAS* 104, 3456-3459.

Kovacs, K.A., Steullet, P., Steinmann, M., Do, K.Q., Magistretti, P.J., Halfon, O., Cardinaux, J.R., 2007. TORC1 is a calcium- and cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. *Proc Natl Acad Sci U S A* 104, 4700-4705.

Lewis, C.M., Ng, M.Y., Butler, A.W., Cohen-Woods, S., Uher, R., Pirlo, K., Weale, M.E., Schosser, A., Paredes, U.M., Rivera, M., Craddock, N., Owen, M.J., Jones, L., Jones, I., Korszun, A., Aitchison, K.J., Shi, J., Quinn, J.P., Mackenzie, A., Vollenweider, P., Waeber, G., Heath, S., Lathrop, M., Muglia, P., Barnes, M.R., Whittaker, J.C., Tozzi, F., Holsboer, F., Preisig, M., Farmer, A.E., Breen, G., Craig, I.W., McGuffin, P., 2010. Genome-wide association study of major recurrent depression in the U.K. population. *Am J Psychiatry* 167, 949-957.

Luppino, F.S., de Wit, L.M., Bouvy, P.F., Stijnen, T., Cuijpers, P., Penninx, B.W., Zitman, F.G., 2010. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry* 67, 220-229.

Marques-Vidal, P., Bochud, M., Mooser, V., Paccaud, F., Waeber, G., Vollenweider, P., 2009. Obesity markers and estimated 10-year fatal cardiovascular risk in Switzerland. *Nutr Metab Cardiovasc Dis* 19, 462-468.

Mastronardi, C., Paz-Filho, G.J., Valdez, E., Maestre-Mesa, J., Licinio, J., Wong, M.L., 2011. Long-term body weight outcomes of antidepressant-environment interactions. *Mol Psychiatry* 16, 265-272.

McGuffin, P., Katz, R., Aldrich, J., 1986. Past and present state examination: the assessment of 'lifetime ever' psychopathology. *Psychol Med* 16, 461-465.

McGuffin, P., Knight, J., Breen, G., Brewster, S., Boyd, P.R., Craddock, N., Gill, M., Korszun, A., Maier, W., Middleton, L., Mors, O., Owen, M.J., Perry, J., Preisig, M., Reich, T., Rice, J., Rietschel, M., Jones, L., Sham, P., Farmer, A.E., 2005. Whole genome linkage scan of recurrent depressive disorder from the depression network study. *Hum Mol Genet* 14, 3337-3345.

Milaneschi, Y., Lamers, F., Mbarek, H., Hottenga, J.J., Boomsma, D.I., Penninx, B.W., 2014. The effect of FTO rs9939609 on major depression differs across MDD subtypes. *Mol Psychiatry* 19, 960-962.

Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.B., Lee, A., Xue, B., Mu, J., Fougelle, F., Ferre, P., Birnbaum, M.J., Stuck, B.J., Kahn, B.B., 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* 428, 569-574.

Nurnberger, J.I., Jr., Blehar, M.C., Kaufmann, C.A., York-Cooler, C., Simpson, S.G., Harkavy-Friedman, J., Severe, J.B., Malaspina, D., Reich, T., 1994. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. *Arch Gen Psychiatry* 51, 849-859.

Nyberg, G., Martensson, E., 1984. Determinations of free fractions of tricyclic antidepressants. *Naunyn-Schmiedeberg's Arch Pharmacol* 327, 260-265.

Penninx, B.W., Beekman, A.T., Smit, J.H., Zitman, F.G., Nolen, W.A., Spinhoven, P., Cuijpers, P., De Jong, P.J., Van Marwijk, H.W., Assendelft, W.J., Van Der Meer, K., Verhaak, P., Wensing, M., De Graaf, R., Hoogendijk, W.J., Ormel, J., Van Dyck, R., Consortium, N.R., 2008. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *International journal of methods in psychiatric research* 17, 121-140.

Preisig, M., Fenton, B.T., Matthey, M.L., Berney, A., Ferrero, F., 1999. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version. *Eur Arch Psychiatry Clin Neurosci* 249, 174-179.

Preisig, M., Waeber, G., Vollenweider, P., Bovet, P., Rothen, S., Vandeleur, C., Guex, P., Middleton, L., Waterworth, D., Mooser, V., Tozzi, F., Muglia, P., 2009. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. *BMC Psychiatry* 9, 9.

Prentice, A.M., Jebb, S.A., 2001. Beyond body mass index. *Obes Rev* 2, 141-147.

Qi, L., Kang, K., Zhang, C., van Dam, R.M., Kraft, P., Hunter, D., Lee, C.H., Hu, F.B., 2008. Fat mass-and obesity-associated (FTO) gene variant is associated with obesity: longitudinal analyses in two cohort studies and functional test. *Diabetes* 57, 3145-3151.

Rivera, M., Cohen-Woods, S., Kapur, K., Breen, G., Ng, M.Y., Butler, A.W., Craddock, N., Gill, M., Korszun, A., Maier, W., Mors, O., Owen, M.J., Preisig, M., Bergmann, S., Tozzi, F., Rice, J., Rietschel, M., Rucker, J., Schosser, A., Aitchison, K.J., Uher, R., Craig, I.W., Lewis, C.M., Farmer, A.E., McGuffin, P., 2012. Depressive disorder moderates the effect of the FTO gene on body mass index. *Mol Psychiatry* 17, 604-611.

Rosenbaum, M., Nicolson, M., Hirsch, J., Heymsfield, S.B., Gallagher, D., Chu, F., Leibel, R.L., 1996. Effects of gender, body composition, and menopause on plasma concentrations of leptin. *J Clin Endocrinol Metab* 81, 3424-3427.

Samaan, Z., Anand, S.S., Zhang, X., Desai, D., Rivera, M., Pare, G., Thabane, L., Xie, C., Gerstein, H., Engert, J.C., Craig, I., Cohen-Woods, S., Mohan, V., Diaz, R., Wang, X., Liu, L., Corre, T., Preisig, M., Kutalik, Z., Bergmann, S., Vollenweider, P., Waeber, G., Yusuf, S., Meyre, D., 2013. The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. *Mol Psychiatry* 18, 1281-1286.

Scuteri, A., Sanna, S., Chen, W.M., Uda, M., Albai, G., Strait, J., Najjar, S., Nagaraja, R., Orru, M., Usala, G., Dei, M., Lai, S., Maschio, A., Busonero, F., Mulas, A., Ehret, G.B., Fink, A.A., Weder, A.B., Cooper, R.S., Galan, P., Chakravarti, A., Schlessinger, D., Cao, A., Lakatta, E., Abecasis, G.R., 2007. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet* 3, 1200-1210.

Sham, P.C., Sterne, A., Purcell, S., Cherny, S., Webster, M., Rijdsdijk, F., Asherson, P., Ball, D., Craig, I., Eley, T., Goldberg, D., Gray, J., Mann, A., Owen, M., Plomin, R., 2000. GENESIS: creating a composite

index of the vulnerability to anxiety and depression in a community-based sample of siblings. *Twin Res* 3, 316-322.

Uher, R., Huezio-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., Barreto, M., Placentino, A., Dernovsek, M.Z., Schulze, T.G., Kalember, P., Zobel, A., Czerski, P.M., Larsen, E.R., Souery, D., Giovannini, C., Gray, J.M., Lewis, C.M., Farmer, A., Aitchison, K.J., McGuffin, P., Craig, I., 2009. Genetic predictors of response to antidepressants in the GENDEP project. *Pharmacogenomics J* 9, 225-233.

Willemsen, G., de Geus, E.J., Bartels, M., van Beijsterveldt, C.E., Brooks, A.I., Estourgie-van Burk, G.F., Fugman, D.A., Hoekstra, C., Hottenga, J.J., Kluff, K., Meijer, P., Montgomery, G.W., Rizzu, P., Sondervan, D., Smit, A.B., Spijker, S., Suchiman, H.E., Tischfield, J.A., Lehner, T., Slagboom, P.E., Boomsma, D.I., 2010. The Netherlands Twin Register biobank: a resource for genetic epidemiological studies. *Twin Res Hum Genet* 13, 231-245.

Wing, J.K., Babor, T., Brugha, T., Burke, J., Cooper, J.E., Giel, R., Jablenski, A., Regier, D., Sartorius, N., 1990. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. *Archives of general psychiatry* 47, 589-593.

Wu, Z., Huang, X., Feng, Y., Handschin, C., Gullicksen, P.S., Bare, O., Labow, M., Spiegelman, B., Stevenson, S.C., 2006. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. *Proc Natl Acad Sci U S A* 103, 14379-14384.

Table 1: Genotype distribution in the total study samples, among MDD subjects and controls

Patients	Total	N (%)			HWE
<i>PsyCoLaus</i>					
<i>rs6510997C>T</i>[§]		CC	CT	TT	
Total	3347	2128 (63.6)	1092 (32.6)	127 (3.8)	0.37
MDD cases	1431	912 (63.7)	468 (32.7)	51 (3.6)	
Controls	1916	1216 (63.5)	624 (32.6)	76 (3.9)	
<i>The Radiant study</i>					
<i>rs3746266A>G</i>		AA	AG	GG	
Total	2842	2173 (76.5)	626 (22.0)	43 (1.5)	0.78
MDD cases	2142	1637 (76.4)	468 (21.9)	37 (1.7)	
Controls	700	536 (76.5)	158 (22.6)	6 (0.9)	
<i>rs2075017T>C</i>[§]					
Total	2160	1357 (62.8)	720 (33.3)	83 (3.9)	0.30
MDD cases	1352	849 (62.8)	450 (33.3)	53 (3.9)	
Controls	808	508 (62.9)	270 (33.4)	30 (3.7)	
<i>NESDA/NTR study</i>					
<i>rs3746266A>G</i>		AA	AG	GG	
Total	4663	3235 (69.4)	1306 (28.0)	122 (2.6)	0.47
MDD cases	1768	1234(69.8)	485 (27.4)	49 (2.8)	
Controls	2895	2001 (69.1)	821 (28.5)	73 (2.5)	
<i>rs6510997C>T</i>					
Total	4663	2952 (63.3)	1522 (32.6)	189 (4.1)	0.68
MDD cases	1768	1124 (63.6)	567 (32.1)	77 (4.4)	
Controls	2895	1828 (63.1)	955 (33.0)	112 (3.9)	

MDD: Major depressive disorder, N: number, HWE: Hardy-Weinberg Equilibrium

§ Both SNPs are in complete linkage disequilibrium ($r^2=1$)

Table 2: Association between *CRTC1 rs6510997C>T* polymorphism and fat mass, BMI and waist circumference in the PsyCoLaus sample, among sex-stratified and MDD subjects and controls

	n	Fat mass ^{£§}		BMI [§]		Waist circumference [§]	
		Estimates (95% C.I.)	p-value	Estimates (95% C.I.)	p-value	Estimates (95% C.I.)	p-value
All subjects	3362	-0.66 (-1.28 to -0.04)	0.04	-0.28 (-0.60 to 0.04)	0.09	-0.70 (-1.64 to 0.24)	0.14
Males	1576	-0.03 (-0.56 to 0.51)	0.92				
Females	1786	-1.08 (-1.81 to -0.34)	0.004				
Subjects with MDD	1434	-1.32 (-2.07 to -0.57)	<0.001				
Controls	1920	-0.01 (-0.60 to 0.57)	0.97				

Models were adjusted for age and sex (when appropriate).

BMI: body mass index, C.I.: confidence interval, MDD: Major depressive disorder

[£] *CRTC1 rs6510997C>T* and MDD status interaction regarding fat mass: p= 0.014

[§] *CRTC1 rs6510997C>T* and sex interaction regarding fat mass: estimate: p=0.026

[§] *CRTC1 rs6510997C>T* and MDD status and/or sex interactions regarding BMI and waist circumference: p>0.05

Table 3: Association between *CRTC1* polymorphisms and BMI in the total, sex-stratified sample and in depressive cases and controls of the Radiant study sample:

	<i>rs3746266A>G</i> [‡]			<i>rs2075017T>C</i> [§]		
	n	Estimates (95% C.I.)	P	n	Estimates (95% C.I.)	p
All subjects ^{&}	2822	-0.67 (-1.13 to -0.21)	0.004	2136	-0.50 (-0.95 to -0.05)	0.03
<i>Male</i>	909	-0.38 (-1.05 to 0.30)	0.28	713	-0.25 (-0.93 to 0.42)	0.46
<i>Female</i>	1916	-0.79 (-1.38 to -0.21)	0.008	1424	-0.62 (-1.20 to -0.04)	0.04
Subjects with MDD	2138	-0.75 (-1.30 to -0.21)	0.007	1346	-0.59 (-1.20 to 0.02)	0.06
Controls	684	-0.41 (-1.20 to 0.39)	0.32	790	-0.32 (-0.95 to 0.31)	0.32

Model were adjusted for age and sex (when appropriate) and principal components
C.I.: confidence interval, MDD: Major depressive disorder

[&] Available subjects with clinical and genetic data.

[‡]*CRTC1 rs3746266A>G* and MDD status and/or sex interactions regarding BMI: p>0.05

[§]*CRTC1 rs2075017T>C* and MDD status and/or sex interactions regarding BMI: p>0.05

Table 4: Association between *CRTC1* polymorphisms and BMI in the total, sex-stratified sample and in depressive cases and controls of the NESDA/NTR study sample:

	n	<i>rs3746266A>G</i> Estimates (SE)	<i>P</i>	<i>rs6510997C>T</i> Estimates (SE)	<i>p</i>
All subjects	4663	-0.047 (0.130)	0.73	0.014 (0.130)	0.91
<i>Male</i>	1676	0.072 (0.202)	0.72	-0.053 (0.193)	0.78
<i>Female</i>	2987	-0.121 (0.179)	0.50	0.046 (0.172)	0.79
Subjects with MDD	1768	0.038 (0.256)	0.88	0.166 (0.245)	0.50
Controls	2895	-0.076 (0.150)	0.61	-0.054 (0.144)	0.71

Model were adjusted for age and sex (when appropriate) and principal components
 SE: standard error, MDD: Major depressive disorder